SecProbe.io

Filing text and metadata
Intelligence Terminal Search Probe Scores Topics IPO Watchlist Monthly Activity About API

SEC Comment Letter for TurnOnGreen, Inc. (TOGI, TOGIW) (CIK 0001349706) (TOGI) — May 11, 2021

TurnOnGreen, Inc. (TOGI, TOGIW) (CIK 0001349706)
Date: May 11, 2021 · CIK: 0001349706 · Accession: 0000000000-21-005974

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 000-52140

Date
May 11, 2021
Author
Not clearly detected
Form
UPLOAD
Company
TurnOnGreen, Inc. (TOGI, TOGIW) (CIK 0001349706)

Letter

United States securities and exchange commission logo May 11, 2021 Vincent Andreula Chief Executive Officer Imperalis Holding Corp. 30 N Gould Street, Suite 11023 Sheridan, Wyoming 82801 Re:Imperalis Holding Corp. Registration Statement on Form 10-12G Filed April 13, 2021 File No. 000-52140 Dear Mr. Andreula: We have reviewed your filing and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to these comments within ten business days by providing the requested information or advise us as soon as possible when you will respond. If you do not believe our comments apply to your facts and circumstances, please tell us why in your response. After reviewing your response to these comments, we may have additional comments. Registration Statement on Form 10 filed April 13, 2021 Business CBD Products, page 1 1.We note your statement that "CBD is derived from industrial hemp, and because of its low Tetrahydrocannabinol (THC) content, is lawful in the United States and has no measurable psychoactive effects." However, we also note that some states restrict the purchase, sale and/or possession of CBD and that CBD products must comply with other applicable laws, such as the FD&C Act. We further note your disclosure that cannabis remains illegal under federal law and "[w]e would likely be unable to execute our business plan if the federal government were to enforce federal law regarding cannabis and applied such laws to low THC containing hemp, or other federal or state laws were to be extended to our business." Please remove or revise your statement as to the legality of CBD accordingly, or provide us with the legal analysis supporting such statement.

FirstName LastNameVincent Andreula Comapany NameImperalis Holding Corp. May 11, 2021 Page 2 FirstName LastName Vincent Andreula Imperalis Holding Corp. May 11, 2021 Page 2 Customers and Marketing, page 5 2.We note your reference to your website: "Our products are currently marketed through our website, cannacuresciences.com." Your website appears not to be working. Please revise your disclosure accordingly. Regulatory Requirements, page 6 3.We note your bullet point list of regulations and/or laws governing your business. Please revise to discuss the effects of the various regulations that you describe here on your business with a view to understanding how the regulations are applicable to you. In this regard, please revise to provide more details concerning government approval of CBD related products. In this regard, we note that the FDA has only approved one CBD product. Please also disclose, if true, that your CBD products have not been approved. Please see Item 101(h)(4)(viii) and Item 101(h)(4)(ix) of Regulation S-K. 4.Please also discuss the testing procedures, if any, for your CBD products, including whether the lab(s) performing tests on your CBD products meet the “ISO 17025” or other applicable standards. If you are not having your CBD products tested please add a risk factor on the potential consequences on your business. Risk Factors Our stock price has been extremely volatile and our common stock is not listed on a national stock exchange; ..., page 13 5.We note your disclosure that "[a]n active public market for our common stock currently exists on the OTC Markets (www.otcmarkets.com) but may not be sustained." However, it appears that OTC Markets has discontinued the display of quotes for your shares on www.otcmarkets.com. Please revise this risk factor to disclose this fact and to discuss the risks to investors of buying your shares given that the OTC Markets Group has designated your securities as 'Caveat Emptor' and placed a skull and crossbones icon next to your stock symbol to "inform investors that there may be reason to exercise additional caution and perform thorough due diligence before making an investment decision" in your securities. General 6.Please acknowledge that your registration statement will become effective by operation of law 60 days from the date you filed it, that you will be responsible for filing reports required by Section 13 of the Securities Exchange Act of 1934 beginning at such time, and that we may continue to comment on your registration statement after the effective date.

FirstName LastNameVincent Andreula Comapany NameImperalis Holding Corp. May 11, 2021 Page 3 FirstName LastName Vincent Andreula Imperalis Holding Corp. May 11, 2021 Page 3 We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. You may contact Scott Anderegg at 202-551-3342 or Lilyanna Peyser at 202-551- 3222 with any questions. Sincerely, Division of Corporation Finance Office of Trade & Services

Show Raw Text
United States securities and exchange commission logo
May 11, 2021
Vincent Andreula
Chief Executive Officer
Imperalis Holding Corp.
30 N Gould Street, Suite 11023
Sheridan, Wyoming 82801
Re:Imperalis Holding Corp.
Registration Statement on Form 10-12G
Filed April 13, 2021
File No. 000-52140
Dear Mr. Andreula:
            We have reviewed your filing and have the following comments.  In some of our
comments, we may ask you to provide us with information so we may better understand your
disclosure.
            Please respond to these comments within ten business days by providing the requested
information or advise us as soon as possible when you will respond.  If you do not believe our
comments apply to your facts and circumstances, please tell us why in your response.
            After reviewing your response to these comments, we may have additional comments.
Registration Statement on Form 10 filed April 13, 2021
Business
CBD Products, page 1
1.We note your statement that "CBD is derived from industrial hemp, and because of its low
Tetrahydrocannabinol (THC) content, is lawful in the United States and has no
measurable psychoactive effects."  However, we also note that some states restrict the
purchase, sale and/or possession of CBD and that CBD products must comply with other
applicable laws, such as the FD&C Act. We further note your disclosure that cannabis
remains illegal under federal law and "[w]e would likely be unable to execute our business
plan if the federal government were to enforce federal law regarding cannabis and applied
such laws to low THC containing hemp, or other federal or state laws were to be extended
to our business." Please remove or revise your statement as to the legality of CBD
accordingly, or provide us with the legal analysis supporting such statement.

 FirstName LastNameVincent Andreula
 Comapany NameImperalis Holding Corp.
 May 11, 2021 Page 2
 FirstName LastName
Vincent Andreula
Imperalis Holding Corp.
May 11, 2021
Page 2
Customers and Marketing, page 5
2.We note your reference to your website:  "Our products are currently marketed through
our website, cannacuresciences.com."  Your website appears not to be working.  Please
revise your disclosure accordingly.
Regulatory Requirements, page 6
3.We note your bullet point list of regulations and/or laws governing your business.  Please
revise to discuss the effects of the various regulations that you describe here on your
business with a view to understanding how the regulations are applicable to you.  In this
regard, please revise to provide more details concerning government approval of
CBD related products.  In this regard, we note that the FDA has only approved one CBD
product.  Please also disclose, if true, that your CBD products have not been
approved.  Please see Item 101(h)(4)(viii) and Item 101(h)(4)(ix) of Regulation S-K.
4.Please also discuss the testing procedures, if any, for your CBD products, including
whether the lab(s) performing tests on your CBD products meet the “ISO 17025” or other
applicable standards.  If you are not having your CBD products tested please add a risk
factor on the potential consequences on your business.
Risk Factors
Our stock price has been extremely volatile and our common stock is not listed on a national
stock exchange; ..., page 13
5.We note your disclosure that "[a]n active public market for our common stock currently
exists on the OTC Markets (www.otcmarkets.com) but may not be sustained."  However,
it appears that OTC Markets has discontinued the display of quotes for your shares on
www.otcmarkets.com.  Please revise this risk factor to disclose this fact and to discuss the
risks to investors of buying your shares given that the OTC Markets Group has designated
your securities as 'Caveat Emptor' and placed a skull and crossbones icon next to your
stock symbol to "inform investors that there may be reason to exercise additional caution
and perform thorough due diligence before making an investment decision" in your
securities.
General
6.Please acknowledge that your registration statement will become effective by operation of
law 60 days from the date you filed it, that you will be responsible for filing reports
required by Section 13 of the Securities Exchange Act of 1934 beginning at such time,
and that we may continue to comment on your registration statement after the effective
date.

 FirstName LastNameVincent Andreula
 Comapany NameImperalis Holding Corp.
 May 11, 2021 Page 3
 FirstName LastName
Vincent Andreula
Imperalis Holding Corp.
May 11, 2021
Page 3
            We remind you that the company and its management are responsible for the accuracy
and adequacy of their disclosures, notwithstanding any review, comments, action or absence of
action by the staff.
            You may contact Scott Anderegg at 202-551-3342 or Lilyanna Peyser at 202-551-
3222 with any questions.
Sincerely,
Division of Corporation Finance
Office of Trade & Services